


US PATENT & TRADEMARK OFFICE

PATENT FULL TEXT AND IMAGE DATABASE



(1 of 1)

United States Patent
Charnock-Jones , et al.

6,011,003
January 4, 2000

FLT-4(FMS-like tyrosine kinase), FLT-15, variants thereof used as growth factor inhibitors

Abstract

Disclosed is an altered, soluble form of the FLT polypeptide being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, the polypeptide comprising five or fewer complete immunoglobulin-like domains, together with pharmaceutical compositions comprising the polypeptide, and various uses thereof.

Inventors: Charnock-Jones; David Stephen (Cambridge, GB); Boocock; Christine Ann (Dundee, GB); Sharkey; Andrew Mark (Cambridge, GB); Smith; Stephen Kevin (Cambridge, GB)

Assignee: Metris Therapeutics Limited (London, GB)

Appl. No.: 750141

Filed: May 12, 1997

PCT Filed: May 26, 1995

PCT NO: PCT/GB95/01213

371 Date: May 12, 1997

102(e) Date: May 12, 1997

PCT PUB.NO.: WO95/33050

PCT PUB. Date: December 7, 1995

Foreign Application Priority Data

May 26, 1994[GB]

9410534

Current U.S. Class: 514/2; 435/69.1; 530/350; 536/23.5

Intern'l Class: C07K 014/71

Field of Search: 536/23.5 435/69.1,7.8,361 530/350 514/2 935/9